Tyck till om SwePub Sök
här!
Search: WFRF:(Linder Stig)
> Gullbo Joachim
> Caulfield Thomas R. >
Synthesis and Evalu...
Synthesis and Evaluation of Derivatives of the Proteasome Deubiquitinase Inhibitor b-AP15
-
- Wang, Xin (author)
- Linköpings universitet,Avdelningen för läkemedelsforskning,Medicinska fakulteten
-
- D´arcy, Padraig (author)
- Linköpings universitet,Karolinska Institutet,Avdelningen för läkemedelsforskning,Medicinska fakulteten
-
- Caulfield, Thomas R. (author)
- Mayo Clin, Dept Mol Neurosci, Jacksonville, FL 32224 USA.
-
show more...
-
- Paulus, Aneel (author)
- Mayo Clin, Dept Canc Biol, Jacksonville, FL 32224 USA.
-
- Chitta, Kasyapa (author)
- Mayo Clin, Dept Canc Biol, Jacksonville, FL 32224 USA.
-
- Mohanty, Chitralekha (author)
- Karolinska Inst, Dept Pathol & Oncol, Canc Ctr Karolinska, S-17176 Stockholm, Sweden.,Karolinska Institute, Sweden
-
- Gullbo, Joachim (author)
- Uppsala universitet,Cancerfarmakologi och beräkningsmedicin,Experimentell och klinisk onkologi,Uppsala University, Sweden
-
- Chanan-Khan, Asher (author)
- Mayo Clin, Dept Canc Biol, Jacksonville, FL 32224 USA.
-
- Linder, Stig (author)
- Linköpings universitet,Karolinska Institutet,Avdelningen för läkemedelsforskning,Medicinska fakulteten,Karolinska Institute, Sweden
-
show less...
-
(creator_code:org_t)
- 2015-05-27
- 2015
- English.
-
In: Chemical Biology and Drug Design. - : Wiley. - 1747-0277 .- 1747-0285. ; 86:5, s. 1036-1048
- Related links:
-
https://europepmc.or...
-
show more...
-
https://liu.diva-por... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
https://urn.kb.se/re...
-
show less...
Abstract
Subject headings
Close
- The ubiquitin-proteasome system (UPS) is increasingly recognized as a therapeutic target for the development of anticancer therapies. The success of the 20S proteasome core particle (20S CP) inhibitor bortezomib in the clinical management of multiple myeloma has raised the possibility of identifying other UPS components for therapeutic intervention. We previously identified the small molecule b-AP15 as an inhibitor of 19S proteasome deubiquitinase (DUB) activity. Building upon our previous data, we performed a structure-activity relationship (SAR) study on b-AP15 and identified VLX1570 as an analog with promising properties, including enhanced potency and improved solubility in aqueous solution. In silico modeling was consistent with interaction of VLX1570 with key cysteine residues located at the active sites of the proteasome DUBs USP14 and UCHL5. VLX1570 was found to inhibit proteasome deubiquitinase activity in vitro in a manner consistent with competitive inhibition. Furthermore, using active-site-directed probes, VLX1570 also inhibited proteasome DUB activity in exposed cells. Importantly, VLX1570 did not show inhibitory activity on a panel of recombinant non-proteasome DUBs, on recombinant kinases, or on caspase-3 activity, suggesting that VLX1570 is not an overtly reactive general enzyme inhibitor. Taken together, our data shows the chemical and biological properties of VLX1570 as an optimized proteasome DUB inhibitor.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine (hsv//eng)
Keyword
- chalcone
- deubiquitinase
- in silico modeling
- inhibitor
- lead optimization
- proteasome
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database